Tuesday, June 16, 2026
The week's signal points in two directions at once: the FDA keeps clearing runway for device makers — exempting more low-risk products from 510(k), accepting de-identified real-world evidence, and approving a first-of-its-kind valve on EHR data alone — while the capital and consolidation story keeps tightening around cardiovascular and neurovascular plays. Easier paths to market, harder competition once you're there..
8 things to watch this week:
1. 🫀 Edwards wins FDA approval for the first dedicated surgical tricuspid valve
Edwards secured approval for Triformis Resilia, the first surgical valve designed specifically for the tricuspid position — and notably, the FDA cleared it without a pivotal trial, relying on a retrospective analysis of real-world off-label use data pulled from EHRs. A meaningful precedent for how evidence packages may be assembled for underserved indications.
MedTech Dive
2. 🧭 FDA expands 510(k) exemptions for the first time since 2019
The agency added five product codes to its list of unclassified devices exempt from premarket notification, bringing the total to 13, and implemented the guidance without prior comment. Part of a broader “less burdensome” posture worth tracking if any of your products sit near these boundaries.
MD+DI
3. 🧭 Most device companies don't fail on technology. They fail on sequencing.
Before you raise, launch a pilot, or scale revenue, small commercialization mistakes can cost months — or millions. RŌG Health's Commercial Readiness Check is a 2-minute diagnostic that shows whether your company is prepared for its next milestone, and points you to where the gaps are.
Sponsored by RŌG Health
4. 🧬 Medtronic closes $550M Scientia Vascular acquisition
Medtronic completed its purchase of the Salt Lake City–based maker of neurovascular access products, joining Boston Scientific (Penumbra) and Stryker (Inari) in the rush to build out stroke-treatment portfolios. Neurovascular is fast becoming the segment everyone wants a position in.
MassDevice
5. 📊 FDA to accept de-identified real-world evidence for select device applications
The agency is dropping the requirement for identifiable individual data in certain device submissions, extending its broader shift toward real-world evidence and new approach methodologies. Paired with the Edwards approval above, the direction of travel on evidence standards is hard to miss.
AJMC
6. 💰 Abbott and Mayo Clinic anchor Star51 Capital’s debut $100M medtech fund
Star51 closed the first tranche of a $100M fund targeting early- and growth-stage companies at the convergence of medtech and AI — spanning interventional therapies, diagnostics, monitoring, and digital health. Strategic-and-provider-anchored capital entering the early-stage market is a useful signal about where the smart money expects the next wave of devices to originate.
FirstWord HealthTech
7. 🩺 Biotronik performs first U.S. implant of its LivIQ leadless pacemaker
The first U.S. case in Biotronik’s BIO-LivIQ pivotal trial puts a third serious player into leadless pacing — its single-device design delivers AV synchrony via atrial far-field sensing, something it says no other intracardiac pacemaker does. With 325 patients planned across 60 sites, it’s a direct challenge to the Abbott–Medtronic duopoly.
Cardiovascular Business
8. 🔧 Medtronic earns CE mark for its Stealth AXiS surgical platform in ENT
Medtronic extended its next-generation ENT navigation-and-robotics platform into Europe, following U.S. clearance earlier this year. Built on its Mazor and StealthStation lineage and designed for both hospitals and ambulatory surgery centers, it’s another step in robotics, pushing past soft-tissue surgery into adjacent specialties.
MPO Magazine
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.